Timothy Cripe P MD, PhD


​ 

Timothy Cripe P MD, PhD
ProfessorCollege of Medicinetimothy.cripe@nationwidechildrens.org
700 Childrens Dr Columbus OH 43205
Phone:(614) 722-3552Fax: (614) 722-3699
  • Translational Therapeutics

General Research Interest

Oncolytic virotherapy, targeted small molecule inhibitors, non-CNS solid tumors in children

Research Description

My laboratory is interested in developing and studying targeted therapeutics for non-CNS solid tumors in children, particularly sarcomas and neuroblastoma. Our efforts are primarily focused on the development of oncolytic virotherapy as well as small molecule targeted inhibitors. Active projects include studies of the mechanism and enhancement of tumor-selective virus delivery for metastatic disease, the role and manipulation of regulatory T cells in the antiviral and antitumor immune response, the utility of incorporating therapeutic transgenes to modify the tumor microenvironment, the effect of small molecule inhibitors combined with oncolytic virus infection, and the effect of oncolytic viruses on cancer stem cells.  

Transinstitutional Work

We have ongoing collaborations with Drs E.A. Chiocca and B. Kaur in the OSUCCC Department of Neurosurgery in the area of oncolytic virotherapy, with Dr. N. Ratner in the Division of Experimental Hematology & Cancer Biology at Cincinnati Children’s Research Foundation in the area of neurofibromatosis and malignant peripheral nerve sheath tumors, and with Dr. S. Wells in the Division of Hematology/Oncology at Cincinnati Children’s Research Foundation in the area of human papillomavirus-associated tumorigenesis.

Current Publications

  • Yoo JY, Hurwitz BS, Bolyard C, Yu JG, Zhang J, Selvendiran K, Rath KS, He S, Bailey Z, Eaves D, Cripe TP, Parris DS, Caligiuri MA, Yu J, Old M, Kaur BBortezomib-induced unfolded protein response increases oncolytic HSV-1 replication resulting in synergistic antitumor effects.Clin Cancer Res 20 3787-98 7/15/2014
  • Wagner LM, Yin H, Eaves D, Currier M, Cripe TPPreclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.Pediatr Blood Cancer in press 4/19/2014
  • Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH, Jegga A, Cripe TP, Ratner NMAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.Oncogene in press 2/10/2014
  • Wu J, Patmore DM, Jousma E, Eaves DW, Breving K, Patel AV, Schwartz EB, Fuchs JR, Cripe TP, Stemmer-Rachamimov AO, Ratner NEGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors.Oncogene 33 173-80 1/9/2014
  • Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller JPilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.Pediatr Blood Cancer 60 1447-51 9/1/2013
  • Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW, Stehn JR, Haass NK, Bonello T, Desouza MA novel class of anticancer compounds targets the actin cytoskeleton in tumor cells.Cancer Res 73 5169-82 8/15/2013
  • Wang PY, Currier MA, Hansford L, Kaplan D, Chiocca EA, Uchida H, Goins WF, Cohen JB, Glorioso JC, van Kuppevelt TH, Mo X, Cripe TPExpression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV.Gene Ther 20 761-9 7/1/2013
  • Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TPVEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.Mol Ther 21 1014-23 5/1/2013
  • Rizvi TA, Brundage ME, Eaves D, Widemann B, Kim MO, Dombi E, Sabo J, Hardiman Dudley A, Niwa-Kawakita M, Page GP, Giovannini M, Aronow BJ, Cripe TP, Ratner N, Jessen WJ, Miller SJ, Jousma E, Wu JMEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.J Clin Invest 123 340-7 1/2/2013
  • Patmore DM, Welch S, Fulkerson PC, Wu J, Choi K, Eaves D, Kordich JJ, Collins MH, Cripe TP, Ratner NIn vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.Cancer Res 72 5317-27 10/15/2012
  • Cripe TP, Miller SJ, Ratner N, Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra ERas-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.Clin Cancer Res 18 5020-30 9/15/2012
  • Cripe TPDiffering approaches to experimental therapeutics: are we a world apart?Mol Ther 20 1649-50 9/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu